You cannot diagnose what you cannot see: The importance of optimized imaging protocols for accurate disease staging and assessment.

Pediatric Blood & CancerVolume 70, Issue 10 e30552 HIGHLIGHT You cannot diagnose what you cannot see: The importance of optimized imaging protocols for accurate disease staging and assessment Nicholas Gottardo, Nicholas Gottardo Department of Paediatric and Adolescent Oncology/Haematology, Perth Children's Hospital, Perth, AustraliaSearch for more papers by this authorMaryam Fouladi, Maryam Fouladi Division of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio, USASearch for more papers by this authorDennis Shaw, Corresponding Author Dennis Shaw [email protected] Department of Radiology, Seattle Children's Hospital, Seattle, Washington, USA Correspondence Dennis Shaw, Department of Radiology, Seattle Children's Hospital, 4800 Sand Point Way NE, Mail Stop MA. 7. 220, Seattle, WA 98105, USA. Email: [email protected]Search for more papers by this author Nicholas Gottardo, Nicholas Gottardo Department of Paediatric and Adolescent Oncology/Haematology, Perth Children's Hospital, Perth, AustraliaSearch for more papers by this authorMaryam Fouladi, Maryam Fouladi Division of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio, USASearch for more papers by this authorDennis Shaw, Corresponding Author Dennis Shaw [email protected] Department of Radiology, Seattle Children's Hospital, Seattle, Washington, USA Correspondence Dennis Shaw, Department of Radiology, Seattle Children's Hospital, 4800 Sand Point Way NE, Mail Stop MA. 7. 220, Seattle, WA 98105, USA. Email: [email protected]Search for more papers by this author First published: 10 July 2023 https://doi.org/10.1002/pbc.30552Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Adamson PC. Improving the outcome for children with cancer: development of targeted new agents. CA Cancer J Clin. 2015; 65(3): 212-220. 2Trout AT, Norris RE, de Blank PMK, Backus LR, Towbin AJ, Nash JM. Clinical trials: a plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Pediatr Blood Cancer. 2023:e30362. 3Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006(24): 4202-4208. 4Michalski JM, Janss AJ, Vezina LG, et al. Children's Oncology Group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2021; 39(24): 2685-2697. 5Jaju A, Li Y, Dahmoush H, et al. Imaging of pediatric brain tumors: a COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper. Pediatr Blood Cancer. 2023; 70(suppl 4):e30147. 6Leary SES, Packer RJ, Li Y, et al. Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children's Oncology Group. JAMA Oncol. 2021; 7(9): 1313-1321. 7Gottardo NG, Leary S, Kang G, et al. How to increase survival in 7 to 10% of patients with average-risk medulloblastoma without new therapies: early prospective neuroradiology screening experience from the Children's Oncology Group. Neuro Oncol. 2020; 22(suppl 3):iii396. Volume70, Issue10October 2023e30552 ReferencesRelatedInformation